An update on the latest developments in the field of CAR-T therapy

Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, outlines the newest developments in chimeric antigen receptor T-cell (CAR-T) remedy. Prof. Chabannon first highlights advances within the manufacturing of a brand new era of CAR-Ts, and talks on the current approval of the BCMA-directed CAR-T ciltacabtagene autoleucel (cilta-cel) in a number of myeloma. Lastly, Prof. Chabannon feedback on the continued discussions on transferring CD19-targeted CAR-Ts from third-line to second-line in lymphoma. This interview passed off on the forty eighth Annual Assembly of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held nearly.

source